Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study

Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study

Abstract Background Pemetrexed and bevacizumab as monotherapies, or in combination, have been approved for maintenance therapy following platinum‐based induction in patients with advanced nonsquamous non‐small cell lung cancer (NSCLC). The differences in the benefits of bevacizumab for treatment dur...

Full description

Bibliographic Details
Main Authors: Ni Jun, Wang Hanping, Si Xiaoyan, Xu Yan, Wang Mengzhao, Zhang Xiaotong, Zhang Li
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:Thoracic Cancer
Subjects:
Antiangiogenic targeted therapy
chemotherapy
pemetrexed
progressive‐free survival
Online Access:https://doi.org/10.1111/1759-7714.13469

Similar Items

Similar Items